åêðáéäåõóçó γ.ν.α.

ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ, ΤΟΜΟΣ 71, ΣΥΜΠΛΗΡΩΜΑ, 2009
447
11. Jansen GA, van Vliet HH, Vermeij H et al. Functional
characteristics of photochemically treated platelets.
Transfusion 2004; 44: 313–319.
12.McCullough J, Vesole DH, Benjamin RJ et al. Therapeutic
efficacy and safety of platelets treated with a
photochemical process for pathogen inactivation: the
SPRINT Trial. Blood 2004; 104: 1534–1541.
13. van Rhenen D, Gulliksson H, Cazenave JP et al. Transfusion
of pooled buffy coat platelet components prepared
with photochemical pathogen inactivation treatment: the
euroSPRITE trial. Blood 2003; 101(6): 2426–2433.
14.Pinkoski T, et al. The INTERCEPT Blood System for
plasma: process validation studies of coagulation factor
activity and yield in two European blood centers. Abstract
presented at American Society of Hematology Annual
Meeting, San Diego, CA; December 4–7, 2004.
15. Corash L. Helinx technology for inactivation of infectious
pathogens and leukocytes in labile blood components:
from theory to clinical application. Transfusion and
Apheresis Science 2001; 25: 179–181.
16. Conlan MG et al. Antibody formation to S-303 treated
RBCs in the setting of chronic RBC transfusion. Abstract
No. 382. Blood 2004; 104: 112a.
17. Snyder E et al. Pathogen inactivated red blood cells using
INACTINE technology demonstrates 24 hours post
transfusion recovery equal to untreated red cells after
42 days of storage. Presented at the American Society
of Hematology, 43rd Annual Meeting, Orlando, FL;
December 2001.
18. AuBuchon JP, Pickard CA, Herschel LH et al. Production
of pathogen-inactivated RBC concentrates using PEN110
chemistry: a phase I clinical study. Transfusion 2002;
42: 146–152.
19. Zavizion B, Serebryanik D, Chapman J et al. Inactivation
of Gram-negative and Gram-positive bacteria in red cell
concentrates using INACTINE PEN110 chemistry. Vox
Sanguinis 2004; 87: 143–149.
20. Li J, de Korte D, Woolum MD et al. Pathogen reduction
of buffy coat platelet concentrates using riboflavin and
light: comparisons with pathogen-reduction technology-treated
apheresis platelet products. Vox Sanguinis
2004; 87: 82–90.
21. Reddy HL, Dayan AD, Cavagnaro J et al. Toxicity testing
of a novel Riboflavin-based technology for pathogen
reduction and white blood cell inactivation. Transfusion
Medicine Reviews, 2008; Vol 22, No 2:133-153.
22. Solheim B. Pathogen reduction of blood components.
Transfusion and Apheresis Science, 2008; 39: 75–82.
23. Klein HG, Anderson D, Bernardi MJ et al. Pathogen
inactivation: making decisions about new technologies.
Report of a consensus conference. Transfusion 2007;
47: 2338-2347.
xxxxxxxxxxx
xxxxxx